Abstract
Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC enzymes, was tested against beta-lactamase-producing bacteria with piperacillin, piperacillin-tazobactam and ceftazidime as partner drugs. In the presence of conalbumin as an iron chelator, Syn 2190 potentiated these drugs against most AmpC producers, although Klebsiella spp. with plasmidic AmpC enzymes were an exception. Potentiation was much weaker without conalbumin, suggesting that Syn 2190 exploits a ferric uptake pathway, as do catecholic cephalosporins. Syn 2190 had little ability to potentiate partner drugs against strains with other beta-lactamase types but, with conalbumin, increased the activity of piperacillin-tazobactam against Escherichia coli transconjugants producing various class A or D enzymes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bacterial Proteins*
-
Ceftazidime / pharmacology
-
Conalbumin / pharmacology*
-
Drug Interactions
-
Drug Synergism
-
Drug Therapy, Combination / pharmacology
-
Enterobacteriaceae / drug effects*
-
Enterobacteriaceae / enzymology
-
Enzyme Inhibitors / pharmacology*
-
Escherichia coli / drug effects
-
Escherichia coli / enzymology
-
Iron Chelating Agents / pharmacology
-
Microbial Sensitivity Tests
-
Monobactams / pharmacology*
-
Penicillanic Acid / analogs & derivatives
-
Penicillanic Acid / pharmacology
-
Piperacillin / pharmacology
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / enzymology
-
Tazobactam
-
beta-Lactamase Inhibitors*
-
beta-Lactamases
Substances
-
Bacterial Proteins
-
Enzyme Inhibitors
-
Iron Chelating Agents
-
Monobactams
-
Syn 2190
-
beta-Lactamase Inhibitors
-
Conalbumin
-
Penicillanic Acid
-
Ceftazidime
-
AmpC beta-lactamases
-
beta-Lactamases
-
Tazobactam
-
Piperacillin